QNCX Stock Forecast & Price Target

Quince Therapeutics is attractive because its lead asset LAM-001 is a differentiated, once-daily inhaled rapamycin designed to target mTOR-driven vascular remodeling rather than just vasodilation, potentially making it a complementary add-on to existing PH-ILD therapies. The investment case is strengthened by encouraging Phase 2a signals in heavily pre-treated patients, including a 68-meter 6MWD gain, 20% to 32% PVR reductions, a 22% NT-proBNP decline, stable-to-improved FVC, and no drug-related SAEs, all on background therapy. It also has multiple catalysts and optionality in BOS and SAPH, while the balance sheet reportedly supports runway through 2028 and about $83M of warrants could extend it into 2029.

Quince Therapeutics is fundamentally challenged by extreme concentration risk, with nearly all valuation tied to a single LAM-001 program whose key PH-ILD data are based on only 10 patients, including just six evaluable patients, making the signal fragile and hard to generalize. The bear case is reinforced by a crowded PH-ILD market where Tyvaso generated about $1.9B in 2025 sales and other products are advancing, so LAM-001 must prove clear differentiation while also overcoming the well-known systemic toxicity concerns of mTOR inhibition, including immunosuppression, hyperlipidemia, and wound-healing issues. Financially, the company is expected to continue net losses and may need additional capital, with the stock potentially pressured if the 1Q28 PH-ILD readout disappoints and cash is estimated at less than $40M.